- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03050268
Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.
While it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.
The purpose of this protocol is to identify novel cancer predisposing genes and/or genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.
PRIMARY OBJECTIVE:
- Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.
SECONDARY OBJECTIVE:
- Identify novel cancer predisposing genes and/or genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.
Study Overview
Status
Conditions
- Pancreatic Cancer
- Hodgkin Lymphoma
- Lynch Syndrome
- Tuberous Sclerosis
- Fanconi Anemia
- AML
- Non Hodgkin Lymphoma
- Familial Adenomatous Polyposis
- Acute Leukemia
- Nevoid Basal Cell Carcinoma Syndrome
- Neurofibromatosis Type 1
- Neuroblastoma
- Retinoblastoma
- MDS
- Rhabdomyosarcoma
- Von Hippel-Lindau Disease
- Adrenocortical Carcinoma
- Neurofibromatosis Type II
- Dyskeratosis Congenita
- Diamond-Blackfan Anemia
- Multiple Endocrine Neoplasia Type 2
- GIST
- Multiple Endocrine Neoplasia Type 1
- Choroid Plexus Carcinoma
- Carney Complex
- Peutz-Jeghers Syndrome
- Hereditary Breast and Ovarian Cancer
- Constitutional Mismatch Repair Deficiency Syndrome
- Li-Fraumeni Syndrome
- BAP1 Tumor Predisposition Syndrome
- DICER1 Syndrome
- PTEN Hamartoma Tumor Syndrome
- Pheochromocytoma/Paraganglioma
- Familial Acute Myeloid Leukemia
- Familial Cancer
- Adenomatous Polyposis
- Emberger Syndrome
- Familial Wilms Tumor
- Familial Neuroblastoma
- Hereditary Paraganglioma-Pheochromocytoma Syndrome
- Juvenile Polyposis
- Melanoma Syndrome
- Noonan Syndrome and Other Rasopathy
- Overgrowth Syndromes
- Rhabdoid Tumor Predisposition Syndrome
- Rothmund-Thomson Syndrome
Detailed Description
During the study, blood samples or other healthy tissue will be obtained from participants, as well as medical and family histories. When possible, leftover tumor samples will also be collected. If participants agree to be re-contacted in the future, they will be asked about once each year to update their health information and family history.
A blood sample will be drawn at St. Jude or at a convenient place of the participant's choice. Saliva collection will be obtained if a blood draw is not possible. For participants who are present at St. Jude, saliva collection will generally be performed only once using a saliva collection kit. However, if the first collection is not sufficient for protocol required studies, then additional saliva samples may need to be collected, for up to a total of 5 occurrences. For non St. Jude participants, or participants who do not wish or cannot come to St. Jude, saliva will be collected locally and shipped back to the St. Jude. A skin sample will be performed as a source of germline DNA from participants who have undergone an allogeneic bone marrow transplant and do not have a source of pre-transplant DNA available. A skin sample will only be obtained one time.
The biological samples will be stored in the St. Jude Biorepository. The DNA of the samples will be studied to determine if there are changes in specific genes that might explain the cancers in the participant or their family members. When available, and if consent is given by the participant, previously collected and stored leftover tumor samples, bone marrow samples or stored DNA may be analyzed.
Genetic variants of interest include: 1) mutations in known genes that may have escaped detection through prior clinical genetic testing; 2) coding mutations predicted to disrupt protein function, particularly in genes and pathways known to be associated with cancer; 3) potential mutations in regulatory regions of the genome, as predicted by epigenetic studies. In some cases, individuals with known predisposing mutations exhibit milder, more severe or atypical phenotypes. Family members who harbor a predisposing mutation but are discordant for a cancer phenotype will be selected for cellular and genetic studies. These will include DNA sequencing and possibly also creation and analysis of induce pluripotent stem cells (iPSC), transcriptome or epigenetic analysis.
All samples will be identified by a code after removal of all personal identifiable information. Samples will remain in the repository for current and future study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jamie L. Maciaszek, PhD
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
Study Contact Backup
- Name: Kim E. Nichols, MD
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Recruiting
- St. Jude Children's Research Hospital
-
Contact:
- Kim E. Nichols, MD
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
-
Principal Investigator:
- Kim E. Nichols, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.
DEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:
In this protocol, the definition of "Familial Cancer" is met if any of the following is present:
- An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR
- An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR
- An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR
- An individual with a congenital cancer diagnosed before 6 months of age; OR
- An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age
º Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.
INCLUSION CRITERIA:
- An individual who meets this protocol's definition of "Familial Cancer," as above.
- Biologic relatives of an individual meeting this protocol's definition of "Familial Cancer," who are either affected or unaffected by cancer.
EXCLUSION CRITERIA:
- An inability or unwillingness of the research participant or his/her legally authorized representative (LAR) to provide written informed consent.
- The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of novel cancer predisposing genes
Time Frame: Up to 20 years following study activation
|
Probands and cancer affected and unaffected relatives from selected families will be sequenced using Whole Genome Sequencing (WGS) or possibly Whole Exome Sequencing (WES) and analyzed to identify new predisposing genetic variants that co-segregate with the tumor phenotype.
Data will be analyzed using annotation and filtering strategies to identify potentially deleterious germline mutations that co-segregate with disease.
|
Up to 20 years following study activation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kim E. Nichols, MD, St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Nervous System Diseases
- Skin Diseases
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Disease
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Congenital Abnormalities
- Bone Marrow Diseases
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Infant, Newborn, Diseases
- Retinal Diseases
- Breast Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Thoracic Neoplasms
- Neuromuscular Diseases
- Otorhinolaryngologic Neoplasms
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neurodegenerative Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Kidney Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Ear Diseases
- Intestinal Neoplasms
- Skin Diseases, Genetic
- Nervous System Neoplasms
- Eye Diseases, Hereditary
- Bone Diseases
- Heredodegenerative Disorders, Nervous System
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Neoplasms, Complex and Mixed
- Cranial Nerve Diseases
- Neoplasms, Connective Tissue
- Neuroendocrine Tumors
- Sarcoma
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Jaw Diseases
- Craniofacial Abnormalities
- Musculoskeletal Abnormalities
- Skin Abnormalities
- Anemia, Hypoplastic, Congenital
- Anemia, Aplastic
- Congenital Bone Marrow Failure Syndromes
- Bone Marrow Failure Disorders
- Malformations of Cortical Development, Group I
- Malformations of Cortical Development
- Nervous System Malformations
- Neuroectodermal Tumors, Primitive
- Abnormalities, Multiple
- Adenomatous Polyps
- Adenoma
- Intestinal Polyposis
- Ovarian Neoplasms
- Neoplasms, Muscle Tissue
- Hyperpigmentation
- Pigmentation Disorders
- Bone Diseases, Developmental
- Odontogenic Cysts
- Jaw Cysts
- Bone Cysts
- Neoplasms, Basal Cell
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neuroectodermal Tumors, Primitive, Peripheral
- Eye Neoplasms
- Retinal Neoplasms
- Adrenal Gland Diseases
- Melanosis
- Cranial Nerve Neoplasms
- Ciliopathies
- Breast Neoplasms
- Myosarcoma
- Angiomatosis
- Neoplasms, Multiple Primary
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Neuroma, Acoustic
- Neurilemmoma
- Neuroma
- Vestibulocochlear Nerve Diseases
- Retrocochlear Diseases
- Myelodysplastic Syndromes
- Red-Cell Aplasia, Pure
- Myxoma
- Heart Neoplasms
- Lentigo
- Neoplasms
- Lymphoma
- Syndrome
- Carcinoma
- Leukemia
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Disease Susceptibility
- Anemia
- Fanconi Anemia
- Rhabdoid Tumor
- Adenomatous Polyposis Coli
- Basal Cell Nevus Syndrome
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Neuroblastoma
- Retinoblastoma
- Endocrine Gland Neoplasms
- Rhabdomyosarcoma
- Von Hippel-Lindau Disease
- Wilms Tumor
- Carcinoma, Basal Cell
- Pheochromocytoma
- Paraganglioma
- Adrenocortical Carcinoma
- Noonan Syndrome
- Neurofibromatosis 2
- Hereditary Breast and Ovarian Cancer Syndrome
- Anemia, Diamond-Blackfan
- Dyskeratosis Congenita
- Multiple Endocrine Neoplasia
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2a
- Tuberous Sclerosis
- Carney Complex
- Peutz-Jeghers Syndrome
- Hamartoma Syndrome, Multiple
- Hamartoma
- Li-Fraumeni Syndrome
- GATA2 Deficiency
- Rothmund-Thomson Syndrome
Other Study ID Numbers
- SJFAMILY
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina